Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Constipation AND Irritable Bowel Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Constipation AND Irritable Bowel Syndrome. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-001248-67 Sponsor Protocol Number: LIN4113 Start Date*: 2014-01-14
    Sponsor Name:almirall
    Full Title: CLINICAL TRIAL PHASE IIIb to evaluate predictors of response to linaclotide in patients with irritable bowel syndrome and explore the impact on intestinal symptoms
    Medical condition: Irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003293-32 Sponsor Protocol Number: Duski2015 Start Date*: 2017-11-06
    Sponsor Name:Academic Medical Center
    Full Title: Multicentre, Randomised, Placebo-Controlled Trial of Mebeverine in Children with Irritable Bowel Syndrome (IBS) or Functional Abdominal Pain - not otherwise specified (FAP-NOS)
    Medical condition: Functional Gastrointestinal Disorders (Irritable Bowel Syndrome or Functional Abdominal Pain - not otherwise specified)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000214-71 Sponsor Protocol Number: NAK-03 Start Date*: 2008-07-01
    Sponsor Name:Laboratorios Menarini S.A. (Menarini Group)
    Full Title: Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome.
    Medical condition: Irritable Bowel Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) SK (Completed) LV (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002752-34 Sponsor Protocol Number: Clin-AGI003-001 Start Date*: 2004-12-20
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AGI 003 IN THE TREATMENT OF NON-CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME.
    Medical condition: Irritable bowel syndrome (not constipation predominant).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10023003 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003770-14 Sponsor Protocol Number: 3030-202-002 Start Date*: 2018-10-11
    Sponsor Name:Allergan LTD
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irrit...
    Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    20.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) HU (Completed) NL (Completed) DE (Prematurely Ended) PL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001955-38 Sponsor Protocol Number: LIN-MD-66 Start Date*: 2021-05-10
    Sponsor Name:Allergan Ltd
    Full Title: A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C)
    Medical condition: Functional Constipation (FC) Irritable bowel syndrome with constipation (IBS-C)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    20.1 10017947 - Gastrointestinal disorders 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018902-35 Sponsor Protocol Number: TC-6499-12-CLP-004 Start Date*: 2010-05-05
    Sponsor Name:Targacept Inc
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Proof of Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominan...
    Medical condition: Constipation Predominant Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024177-39 Sponsor Protocol Number: RIBS-MIC/002/2010 Start Date*: 2011-02-01
    Sponsor Name:ALFA WASSERMANN
    Full Title: Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.
    Medical condition: Non constipation Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000818-29 Sponsor Protocol Number: MCP-103-403 Start Date*: 2016-08-08
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrom...
    Medical condition: Irritable Bowel Syndrome with Constipation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000550-12 Sponsor Protocol Number: NRL920-01/2008 (IBSc) Start Date*: 2008-11-06
    Sponsor Name:Norgine Pharmaceuticals Ltd
    Full Title: A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® with Placebo in Patients with Constipation Associated...
    Medical condition: Constipation associated with Irritable Bowel Syndrome (IBS-C).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010774 Constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-023958-36 Sponsor Protocol Number: 2011_HV_M2 Start Date*: 2011-09-02
    Sponsor Name:Mª Antònia Perelló Juan
    Full Title: Ensayo clínico aleatorizado de fase IV, en secuencia cruzada, doble ciego, comparando la influencia de la flora intestinal productora del gas metano en la respuesta al tratamiento del estreñimiento...
    Medical condition: Estreñimiento crónico funcional
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10066868 Constipation predominant irritable bowel syndrome LLT
    13.1 10017947 - Gastrointestinal disorders 10063582 Constipation chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002087-10 Sponsor Protocol Number: 1062.7 Start Date*: 2007-08-28
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double -blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops 10 mg administere...
    Medical condition: To compare the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops to placebo in patients with functional constipation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010774 Constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001203-36 Sponsor Protocol Number: BHT-II-002 Start Date*: 2019-01-09
    Sponsor Name:4D Pharma Plc
    Full Title: A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bow...
    Medical condition: Irritable Bowel Syndrome (IBS), subtypes IBS-C and IBS-D
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    20.1 100000004856 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001199-39 Sponsor Protocol Number: MulticenterEbastineIBS Start Date*: 2013-11-21
    Sponsor Name:KULeuven
    Full Title: Histamine 1 receptor antagonist ebastine as novel treatment in IBS
    Medical condition: Patients who suffer from irritable bowel syndrome which are diarrhea predominant and mixed (alteration of constipation and diarrhea)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019343-20 Sponsor Protocol Number: 654-002 Start Date*: 2010-10-15
    Sponsor Name:LOTUS PHARMACEUTICAL CO., LTD.
    Full Title: A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL...
    Medical condition: Diarrhoea predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048571 Irritable bowel syndrome aggravated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002017-28 Sponsor Protocol Number: LinaclotideRectumColon Start Date*: 2014-07-16
    Sponsor Name:KULEUVEN
    Full Title: ROLE OF THE TYPE AND SITE OF DISTENSION IN THE EVALUATION OF DRUGS EFFICACY IN MODULATING THE SENSORY AND MOTOR RESPONSE OF THE DESCENDING COLON AND THE RECTUM IN MAN
    Medical condition: HEALTHY SUBJECTS AND PATIENTS WITH IRRITABLE BOWEL SYNDROME
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003468-30 Sponsor Protocol Number: SAG/0211PFC-1131 Start Date*: 2014-09-24
    Sponsor Name:Sucampo Pharma Europe Ltd.
    Full Title: A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional...
    Medical condition: functional constipation in paediatric patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-004264-23 Sponsor Protocol Number: GL61-001 Start Date*: 2006-01-31
    Sponsor Name:Gastrotech Pharma A/S
    Full Title: A randomized, double-blind, placebo controlled, cross-over, multi-center study to assess the effect of the GLP-1 analogue LY307161 in patients suffering from Irritable Bowel Disease
    Medical condition: Irritable Bowel Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004519-31 Sponsor Protocol Number: ENTERL08784 Start Date*: 2019-01-31
    Sponsor Name:Sanofi
    Full Title: Randomized, placebo-controlled, clinical trial to evaluate the efficacy of probiotic Bacillus clausii in the treatment of pediatric patients with irritable bowel syndrome
    Medical condition: Irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003221-22 Sponsor Protocol Number: TAK-555-3010 Start Date*: 2024-01-15
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting o...
    Medical condition: Constipation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 06:22:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA